Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon-β for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential Efficacy
- 1 January 2010
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 21 (1), 51-64
- https://doi.org/10.1089/hum.2009.088
Abstract
Vesicular stomatitis virus (VSV) has shown promise as an oncolytic agent, although unmodified VSV can be neurotoxic. To avoid toxicity, a vector was created by introducing the interferon-β (IFN-β) gene (VSV.IFN-β). We conducted this study to determine the ability of VSV.IFN-β to lyse human cancer (mesothelioma) cells and to evaluate the potential of this recombinant virus for clinical translation. Four normal human mesothelial and 12 mesothelioma cell lines were tested for their susceptibility to VSV vectors in vitro. VSV.hIFN-β did not cause cytotoxicity in any normal lines. Only 4 of 12 lines were effectively lysed by VSV.hIFN-β. In the eight resistant lines, pretreatment with IFN-β prevented lysis of cells by VSV.GFP, and VSV infection or addition of IFN-β protein resulted in the upregulation of double-stranded RNA-dependent protein kinase (PKR), myxovirus resistance A (MxA), and 2′,5′-oligo-adenylate-synthetase (2′5′-OAS) mRNA. In the susceptible lines, there was no protection by pretreatment with IFN-β protein and no IFN- or VSV-induced changes in PKR, MxA, and 2′5′-OAS mRNA. This complete lack of IFN responsiveness could be explained by marked downregulation of interferon alpha receptors (IFNARs), p48, and PKR in both the mesothelioma cell lines and primary tumor biopsies screened. Presence of p48 in three tumor samples predicted responsiveness to IFN. Our data indicate that many mesothelioma tumors have partially intact IFN pathways that may affect the efficacy of oncolytic virotherapy. However, it may be feasible to prescreen individual susceptibility to VSV.IFN-β by immunostaining for the presence of p48 protein.Keywords
This publication has 44 references indexed in Scilit:
- Expression of IFN-β Enhances Both Efficacy and Safety of Oncolytic Vesicular Stomatitis Virus for Therapy of MesotheliomaCancer Research, 2009
- Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysisProceedings of the National Academy of Sciences of the United States of America, 2008
- Oncolytic Efficacy of Recombinant Vesicular Stomatitis Virus and Myxoma Virus in Experimental Models of Rhabdoid TumorsClinical Cancer Research, 2008
- Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neuInternational Journal of Cancer, 2007
- Variable Deficiencies in the Interferon Response Enhance Susceptibility to Vesicular Stomatitis Virus Oncolytic Actions in Glioblastoma Cells but Not in Normal Human Glial CellsJournal of Virology, 2007
- Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral ImmunityMolecular Therapy, 2007
- Advances in the diagnosis, evaluation, and management of malignant pleural mesotheliomaRespirology, 2005
- Vesicular stomatitis virus: re-inventing the bulletTrends in Molecular Medicine, 2004
- Vesicular Stomatitis Virus (VSV) Therapy of TumorsIUBMB Life, 2000
- Human Renal Cancers Resistant to IFN's Antiproliferative Action Exhibit Sensitivity to IFN's Gene-Inducing and Antiviral ActionsJournal of Urology, 1996